evolocumab

Ligand id: 7343

Name: evolocumab

References
1. Abifadel M, Varret M, Rab├Ęs JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D et al.. (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Nat. Genet.34 (2): 154-6. [PMID:12730697]
2. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Arterioscler. Thromb. Vasc. Biol.24 (8): 1454-9. [PMID:15178557]
3. Jackson SM, Shan B, Shen W, King CT. 
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9).
Patent number: US8030457. Assignee: Amgen, Inc.. Priority date: 23/08/2007. Publication date: 04/10/2011.
4. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM et al.. (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events.
N. Engl. J. Med.,  [Epub ahead of print]. [PMID:25773607]
5. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. (2012)
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
JAMA308 (23): 2497-506. [PMID:23128163]